FDA Approves Jardiance to Reduce Cardiovascular Death in Adults with Type 2 Diabetes

Study links Jardiance to improved survival in patients with type 2 diabetes with cardiovascular disease

Silver Spring, Maryland–(ENEWSPF)–December 2, 2016. The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

“Cardiovascular disease is a leading cause of death in adults with type 2 diabetes mellitus,” said Jean-Marc Guettier, M.D., C.M., director of the…